STOCK TITAN

Gilead Sciences (GILD) DEF 14A Filings

GILD NASDAQ

Here are the DEF 14A proxy statements from Gilead Sciences Inc (GILD) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow GILD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GILD filings page.

Rhea-AI Summary

Gilead Sciences, Inc. presents its 2026 annual meeting proxy, highlighting strong 2025 performance and several key voting items. Total 2025 product sales were $28.9 billion, with HIV product sales of $20.8 billion, representing 6% year-over-year growth. Base business revenues excluding Veklury were $28.0 billion, up nearly $1.2 billion, or 4%, and the non-GAAP operating margin was 45%. Gilead returned $5.9 billion to shareholders through $4.0 billion in dividends and $1.9 billion in share repurchases, contributing to a 37% total shareholder return for 2025.

The Board asks stockholders to elect nine directors, ratify Ernst & Young LLP as auditor, approve executive compensation on an advisory basis, and approve an amended and restated 2022 Equity Incentive Plan that adds 47,750,000 shares for issuance and extends the plan to March 11, 2036. The Board recommends “FOR” Proposals 1–4 and “AGAINST” three stockholder proposals on board chair independence, patent exclusivity reporting, and ESG/DEI compensation metrics.

Strategically, Gilead underscores HIV leadership, oncology and inflammation pipeline depth, and a planned $32 billion U.S. manufacturing and R&D investment through 2030, projected to generate $43 billion in U.S. economic value. The 2026 annual meeting will be held via virtual webcast on April 30, 2026.